{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-326784","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2026-07-31T11:23:10+00:00","discovered_at":"2026-07-31T11:25:00.296398+00:00","generated_at":"2026-07-31T11:25:13.177922+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax Therapeutics Q2 net loss $17.8M; cash $118M; Phase 3 LEVEL topline data expected Aug 2026","bullets":["Net loss of $17.8M for Q2 2026, compared to $10.9M in Q2 2025.","Cash and cash equivalents of $118.0M as of June 30, 2026; cash runway extended through Q2 2028.","R&D expenses rose to $12.9M from $6.1M, driven by Phase 3 LEVEL and LEVEL-2 trials.","Proceeds of $13.4M from warrant exercises in Q2 2026.","Topline data from Phase 3 LEVEL trial expected in August 2026; LEVEL-2 enrollment targeted by end of 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-326784","json":"https://secwatch.observer/filing/0001193125-26-326784.json","markdown":"https://secwatch.observer/filing/0001193125-26-326784.md","text":"https://secwatch.observer/filing/0001193125-26-326784.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/0001193125-26-326784-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/d90330d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T11:25:13.177922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}